rs11055387 - EMP1 - LINC01559
Magnitude 4.5 · 1 study on file
Reported associations
-
Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies - Unknown journal (n.d.) · Unknown authors · PubMed 23377640
ABSTRACT: Objective: Indirect evidence suggests that common genetic variation contributes to individual differences in antidepressant efficacy among individuals with major depressive disorder, but previous studies may have been underpowered to detect these effects. Method: A meta-analysis was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Drugs for Depression [GENDEP] project, the Munich Antidepressant Response Signature [MARS] project, and the Sequenced Treatment Alternatives to Relieve Depression [STAR*D] study), which included 2,256 individuals of Northern European descent with major depressive disorder, and antidepressant treatment outcomes were prospectively collected. After imputation, 1.2 million single-nucleotide polymorphisms were te
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Discuss depression predisposition with provider Moderate
The C allele is associated with increased genetic risk for major depressive disorder
Share this genetic finding with your healthcare provider to develop a monitoring and prevention plan
Screening
-
Periodic mental health screening Moderate
Genetic variant rs11055387 is associated with significantly increased risk of major depressive disorder
Consider periodic screening using validated tools like PHQ-9